Inevitable Progress-Relying on the Immune System, Not Chance.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34848533.
- Also identified by DOI 10.1158/1078-0432.CCR-21-3739.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Locoregional recurrence of head and neck cancer after curative therapy portends a poor prognosis even when resectable. Immunotherapy has opened the door to novel strategic approaches in the curative treatment paradigm. Potentially improving outcomes for patients with recurrent, resectable disease through combination immune modulators highlights a new frontier.<i>See related article by Hanna et al., p. 468</i>.
Medical subject headings
- Head and Neck Neoplasms
- Neoplasm Recurrence, Local